Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: Three cases

Spinal Cord

Volumn 36, Issue 3, 1998, Pages 147-155

  Potter, P J ^a   Hayes, K C ^a   Hsieh, J T C ^a   Delaney, G A ^a   Segal, J L ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

4 aminopyridine; Motor evoked potentials; Pharmacokinetics; Spasticity; Spinal cord injury

Indexed keywords

4 AMINOPYRIDINE;

ADULT; ARM; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DRUG CAPSULE; DRUG ELIMINATION; ENDURANCE; FEMALE; GAIT; HAND FUNCTION; HUMAN; INTESTINE FUNCTION; LEG; LIVER TOXICITY; MALE; MALE GENITAL SYSTEM FUNCTION; MUSCLE STRENGTH; NEPHROTOXICITY; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; QUADRIPLEGIA; SENSATION; SEROLOGY; SPASTICITY; SPINAL CORD INJURY; SPINAL CORD LESION; STANDING; TIME; TREATMENT OUTCOME; URINALYSIS; VERTIGO;

EID: 0031888625     PISSN: 13624393     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.sc.3100559     Document Type: Article

References (66)

1. Hayes KC et al. Effects of intravenous 4-aminopyridine on neurological function in chronic spinal cord injured patients: Preliminary observations. Proc IBRO World Conf Neurosci 1991b; 345:(Abstr) P53.27.
2. Hayes KC. et al. Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 1993; 31: 216-224.
3. Hayes KC et al. 4-aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J Neurotrauma 1994; 11: 433-446.
4. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993; 10: 1-8.
5. Waxman SG. Aminopyridines and the treatment of spinal cord injury. J Neurotrauma 1993; 10: 19-24.
6. Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and Tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol (Lond) 1981; 313: 301-315.
7. Bowe CM, Kocsis JD, Targ EF, Waxman SG. Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers. Ann Neurol 1987; 22: 264-268.
8. Sherratt RM, Bostock H, Sear TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibers. Nature 1980; 283: 570-572.
9. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989; 22: 47-52.
10. Targ EF, Kocsis JD. 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985; 328: 358-361.
11. Bowman WC, Savage AO. Pharmacological actions of aminopyridine and related compounds. Rev pure Appl Pharmacol 1981; 2: 317-371.
12. Glover WE. The Aminopyridines. Gen Pharmacol 1982; 13: 259-285.
13. Hayes KC. 4-aminopyridine and spinal cord injury: a review. Restor Neurol & Neurosci 1994; 6: 259-270.
14. Soni N, Kam P. 4-aminopyridine - A review. Anaesth Intens Care 1982; 10: 120-126.
15. Thesleff S. Aminopyridine and synaptic transmission. Neurosciences 1980; 5: 1413-1419.
16. Gardner DM, Hayes KC, Delaney GA. Potter PJ (1996) Biomechanics of ankle joint hypertonus in spinal cord injured patients: An analytic approach to quantifying spasticity. Proceedings Australasian Biomechanics Conference, Univ. of Sydney, Australia, February 1 2.
17. Jasper HH. The ten-twenty electode system of the International Federation. Electroencephalogr Clin Neurophysiol 1958; 10: 371-375.
18. Wolfe DL, Hayes KC, Potter PJ, Delaney GA. Conditioning lower limb H-reflexes by transcranial magnetic stimulation of motor cortex reveals preserved innervation in SCI patients. J Neurotrauma 1996; 13: 281-291.
19. Qiao J et al. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury. J Neurotrauma 1997; 14: 125-149.
20. Uges DRA et al. 4-aminopyridine kinetics. Clin Pharmacol Ther 1982; 31: 587-593.
21. Agoston S, Van Weerden T, Westra P, Brockert A. Effects of 4-aminopyridine in Eaton Lambert Syndrome. Br J Anaesth 1978; 50: 383-385.
22. Booij IHDJ, Miller RD, Crul JF. Neostigmine and 4-aminopyridine antagonism of lincomycin-pancuronium neuromuscular blockade in man. Anaeth Anal 1978; (Clev) 57: 316-321.
23. Paskov DS, Agoston S, Bowman WC. 4-aminopyridine hydrochloride (Pymadin) (1986) In: New Neuromuscular Blocking Agents - Basic and Applied Aspects, DA Charkavich (Ed). Handbook of Experimental Pharmacology, Vol 870, Springer-Verlag, pp. 679-717.
24. Sia RI et al. Effects of the analeptic drug, 4-aminopyridine upon postoperative respiratory depression in patients, A preliminary study. Acta Anaesth Belg 1979; 30(Suppl): 195-199.
25. Wesseling H, Agoston S. Effects of 4-aminopyridine in elderly patients with Alzheimer's Disease. The New Engl J Med 1984; 310: 988-989.
26. Ball AP et al. Human botulism caused by clostridium botulinum type e - The Birmingham Outbreak. Quart J Med 1979; 48: 473-491.
27. Murray NMF, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981; 31: 265-271.
28. Lundh H, Nilsson O, Rosen I. Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry 1979; 42: 171-175
29. Lundh H, Nilsson O, Rosen I. 4-aminopyridine - A new drug tested in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry 1977; 40: 1109-1112.
30. Bever CT Jr. The current status of studies of animopyridines in patients with multiple sclerosis. Annals of Neurology 1994; 36(Suppl): S118-121.
31. Bever CT Jr et al. The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind. concentration-controlled, crossover trial. Neurology 1994; 44: 1054-1059.
32. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990; 27: 186-192.
33. Davis FA, Stefoski D, Quandt FN. Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis. Annals of Neurology 1995; 37: 684.
34. Jones RE et al. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983; 60: 353-362.
35. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple selerosis: long-term efficacy and safety. Arch Neurol 1494; 51: 292-296.
36. Polman CH et al. 4-aminopyridine is superior to 3,4-Diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994; 51: 1136-1139.
37. Smits RC et al. The effects of 4-aminopyridine in cognitive function in patients with multiple sclerosis: A pilot study. Neurology 1994; 44: 1701-1705.
38. Stefoski DF, David FA, Faut M, Schauf CL. 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987; 21: 71-77.
39. Stefoski D et al. 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1991; 21: 71-77.
40. van Diemen HA et al. The effect of 4-aminopyridine on the clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind. crossover study. Ann Neurol 1992; 32: 123-130.
41. Segal JL, Brunneman SR, Eltorai IM, Vulpe M. Decreased systemic clearance of lorazepam in humans with spinal cord injury. J Clin Pharmacol 1991; 31: 651-656.
42. Felts PA, Smith KJ. The use of potassium channel blocking agents in the therapy of demyelinating disease. Annals of Neurology 1994; 36: 454.
43. Fastier FN, McDowall MA. Analgesic activity of 4-methyl-2-amino-pyridine and of some related compounds. Australian J Biological Sci 1958; 36: 491-498.
44. Saade N, Jabbur SJ, Wall PD. Effects of 4-aminopyridine, GABA and bicuculline on cutaneous receptive fields of cat dorsal horn neurons. Brain Research 1985; 344: 356-359.
45. Kocsis JD, Bowe CM, Waxman SG, Different effects of 4-aminopyridine on sensory and motor fibers: Pathogenesis of paresthesias. Neurology 1986; 36: 117-120.
46. Kirchoff C, Leah JD, Jung S, Reeh PW. Excitation of cutaneous sensory nerve endings in the rat by 4-aminopyridine and tetraethylammonium. J Neurophysiol 1992; 67: 125-131.
47. Saade NE et al. Cutaneous receptive field alterations induced by 4-aminopyridine. Brain Research 1982; 232: 177-180.
48. Kita T, Kita H, Kitai ST. Effects of 4-aminopyridine (4-AP) on rat neostriatal neurons in an in vitro slice preparation. Brain Research 1985; 361: 10-18.
49. Jankowska E, Lundberg A, Rudomin P, Sykova E. Effects of 4-aminopyridine on synaptic transmission in the cat spinal cord. Brain Research 1982; 240: 117-129.
50. Lemeignan M. Analysis of the action of 4-aminopyridine on the cat lumbar spinal cord I. Modification of the afferent volley, the monosynaptic discharge, amplitude and the polysynaptic evoked responses. Neuropharmacology 1972; 11: 551-558.
51. Lemeignan M. Analysis of the effect of 4-aminopyridine on the lumbar spinal cord of the cat - II. Modification of certain spinal inhibitory phenomena post-tetanic potentiation and dorsal root potential. Neuropharmacology 1973; 12:641-651.
52. Anden NE, Leander S. Effects of 4-aminopyridine on the turnover of monoamines in the central nervous system of the rat. J Neurol Trans 1979; 44: 1-12.
53. Blight AR, Gruner JA. Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J Neurol Sci 1987; 87: 145-159.
54. Blight AR, Toombs JP, Bauer MS, Widmer WR. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: A Phase I clinical trial. J Neurotrauma 1991; 8: 103-119.
55. Pratt K, Toombs JP, Widmer WR, Borgens RB. Plasma and cerebrospinal fluid concentrations of 4-aminopyridine following intravenous injection and metered intrathecal delivery in canines. J Neurotrauma 1995; 12: 23-39.
56. Smeets JW, Kunst MW. Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 1995; 139: 2667-2669.
57. Spyker DA, Lynch S.Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: Report of three cases. Clin Toxicol 1980; 16: 487-497.
58. Stork CM, Hoffman RS. Characterization of 4-aminopyridine in overdose. J Toxicology - Clinical Toxicology 1994; 32: 584-587.
59. Kim YI, Goldner MM, Sanders DB. Facilitator effects of 4-aminopyridine on normal neuromuscular transmission. Muscle & Nerve 1980; 3: 105-111.
60. Molgo J, Lundh H, Thesleff S. Potency of 3,4 diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmissions and the effect of pH changes. Eur J Pharmacol 1980; 61: 25.
61. Zangger P. The effect of 4-aminopyridine on the spinal locomotor rhythm induced by L-Dopa. Brain Research 1981; 215: 211-223.
62. Molgo J, Lemeignan M, Lechat P. Effects of 4-aminopyridine at the frog neuromuscular junction. J Pharmacol Exp Ther 1977; 203: 653-663.
63. Saade NE, Chanelet J, Lonchampt P. Action facilitatrice de microinjection de 4-aminopyridine sur les activities medullaries reflexes de la Grenouille. CR Soc Biol 1971; 165: 2069-2078.
64. Avoli M, Perreault P, Olivier A, Villemure J-G. 4-aminopyridine induces a long-lasting depolarizing GABA-ergic potential in human neocortical and hippocampal neurons maintained in vitro. Neuroscience Letters 1988; 94: 217-332.
65. Jankowska E, Lundberg A, Rudomin P, Sykova E. Effects of 4-aminopyridine on transmission in excitatory and inhibitory synapses in the spinal cord. Brain Research 1977; 136: 387-388.
66. Agostin S et al. Antagonism of Ketamine-Diazepam anaesthesia by 4-aminopyridine in human volunteers. Br J Anaesth 1980; 52: 367-370.